AVIR
Price
$2.91
Change
-$0.00 (-0.00%)
Updated
Sep 26, 03:24 PM (EDT)
Capitalization
230.93M
41 days until earnings call
OCUL
Price
$12.53
Change
+$0.28 (+2.29%)
Updated
Sep 26, 04:43 PM (EDT)
Capitalization
2.13B
45 days until earnings call
Interact to see
Advertisement

AVIR vs OCUL

Header iconAVIR vs OCUL Comparison
Open Charts AVIR vs OCULBanner chart's image
Atea Pharmaceuticals
Price$2.91
Change-$0.00 (-0.00%)
Volume$250
Capitalization230.93M
Ocular Therapeutix
Price$12.53
Change+$0.28 (+2.29%)
Volume$1.45K
Capitalization2.13B
AVIR vs OCUL Comparison Chart in %
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. OCUL commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Buy and OCUL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (AVIR: $2.91 vs. OCUL: $12.24)
Brand notoriety: AVIR and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 69% vs. OCUL: 110%
Market capitalization -- AVIR: $230.93M vs. OCUL: $2.13B
AVIR [@Biotechnology] is valued at $230.93M. OCUL’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than AVIR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 3 bullish TA indicator(s).

  • AVIR’s TA Score: 4 bullish, 6 bearish.
  • OCUL’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, AVIR is a better buy in the short-term than OCUL.

Price Growth

AVIR (@Biotechnology) experienced а -2.02% price change this week, while OCUL (@Biotechnology) price change was -3.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.17%. For the same industry, the average monthly price growth was +9.43%, and the average quarterly price growth was +55.19%.

Reported Earning Dates

AVIR is expected to report earnings on Nov 06, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.13B) has a higher market cap than AVIR($231M). OCUL YTD gains are higher at: 43.326 vs. AVIR (-13.134). AVIR has higher annual earnings (EBITDA): -156.2M vs. OCUL (-200.5M). OCUL (391M) and AVIR (380M) have equal amount of cash in the bank . AVIR has less debt than OCUL: AVIR (1.25M) vs OCUL (76.9M). OCUL has higher revenues than AVIR: OCUL (56.7M) vs AVIR (0).
AVIROCULAVIR / OCUL
Capitalization231M2.13B11%
EBITDA-156.2M-200.5M78%
Gain YTD-13.13443.326-30%
P/E RatioN/AN/A-
Revenue056.7M-
Total Cash380M391M97%
Total Debt1.25M76.9M2%
FUNDAMENTALS RATINGS
AVIR vs OCUL: Fundamental Ratings
AVIR
OCUL
OUTLOOK RATING
1..100
5383
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
9687
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8740
P/E GROWTH RATING
1..100
94100
SEASONALITY SCORE
1..100
4075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (35) in the Biotechnology industry is in the same range as OCUL (53) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (87) in the Pharmaceuticals Other industry is in the same range as AVIR (96) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's SMR Rating (97) in the Biotechnology industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for AVIR (87) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than AVIR’s over the last 12 months.

AVIR's P/E Growth Rating (94) in the Biotechnology industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIROCUL
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 24 days ago
79%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FUPPF48.00N/A
N/A
FUCHS SE
SVNDF13.60N/A
N/A
Seven & I Holdings Co., Ltd.
PBTDF0.80N/A
N/A
PLOVER BAY TECHNOLOGIES LTD.
OGOFF0.47-0.01
-1.35%
Organto Foods Inc.
HCNWF0.06-0.01
-12.84%
Hypercharge Networks Corp.

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with XENE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+0.34%
XENE - AVIR
45%
Loosely correlated
-0.19%
NUVL - AVIR
41%
Loosely correlated
-2.54%
NRIX - AVIR
40%
Loosely correlated
-4.25%
ATXS - AVIR
39%
Loosely correlated
-1.65%
OCUL - AVIR
39%
Loosely correlated
-2.55%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-2.55%
EYPT - OCUL
65%
Loosely correlated
-6.32%
IDYA - OCUL
56%
Loosely correlated
+0.08%
NRIX - OCUL
56%
Loosely correlated
-4.25%
IMVT - OCUL
55%
Loosely correlated
+1.36%
CRNX - OCUL
55%
Loosely correlated
+2.02%
More